Balyasny Asset Management
AXSM icon

Balyasny Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Balyasny Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,900
Closed -$720K – 2906
2025
Q2 		$720K Buy
6,900
+4,200
+156% +$445K ﹤0.01% 2159
2025
Q1 		$315K Buy
+2,700
New +$308K ﹤0.01% 2439
2022
Q4 		– Sell
-40,000
Closed -$1.78M – 2774
2022
Q3 		$1.78M Sell
40,000
-60,000
-60% -$3M 0.01% 1550
2022
Q2 		$3.83M Buy
+100,000
New +$3.16M 0.01% 1065

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Balyasny Asset Management's AXSM Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 76,250 shares worth $18.7M. The stake represents 0.02% of the portfolio and ranks #753 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in AXSM as recently as Q1 2025.

Balyasny Asset Management first reported a position in AXSM in Q1 2018 and has held it in 9 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Balyasny Asset Management held 76,250 shares of Axsome Therapeutics worth $18.7M as of Q2 2026.
  • Axsome Therapeutics was a new Balyasny Asset Management position in Q2 2026.
  • Axsome Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #753 holding.
  • Balyasny Asset Management first reported a position in Axsome Therapeutics in Q1 2018 and has held it in 9 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.